

**Follow-up Time After Dose 2 – Phase 2/3 Subjects  $\geq$ 16 Years of Age and With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population**

	Vaccine Group (as Randomized)		
	BNT162b2 (30 $\mu$ g) (N <sup>a</sup> =21047) n <sup>b</sup> (%)	Placebo (N <sup>a</sup> =21210) n <sup>b</sup> (%)	Total (N <sup>a</sup> =42257) n <sup>b</sup> (%)
Subjects (%) with length of follow-up of:			
Original blinded placebo-controlled follow-up period			
<2 Months	840 (4.0)	910 (4.3)	1750 (4.1)
$\geq$ 2 Months to <4 months	7411 (35.2)	7851 (37.0)	15262 (36.1)
$\geq$ 4 Months to <6 months	11031 (52.4)	11158 (52.6)	22189 (52.5)
$\geq$ 6 Months	1765 (8.4)	1291 (6.1)	3056 (7.2)
<p>Note: Human immunodeficiency virus (HIV)-positive subjects are not included in this summary.</p> <p>a. N = number of subjects in the specified group, or the total sample. This value is the denominator for the percentage calculations.</p> <p>b. n = Number of subjects with the specified characteristic.</p> <p>PFIZER CONFIDENTIAL SDTM Creation: 25MAR2021 (23:24) Source Data: adsl Table Generation: 13AUG2021 (16:37)            (Cutoff Date: 13MAR2021, Snapshot Date: 25MAR2021) Output File: ./nda2_unblinded/C4591001_BLA_RR/adsl_fu_d2_p3_nohiv_ge16_eval</p>			